Health Care · Pharmaceutical Preparations

ZVRA ZEVRA THERAPEUTICS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 143464797 filings
Russell 2000

ZVRA at a glance

ZEVRA THERAPEUTICS, INC. (ZVRA, SEC CIK 1434647) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.5 million (up 350.9% from FY2024) and net income of $83.2 million. Diluted EPS was $1.35.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ZEVRA THERAPEUTICS, INC. (ZVRA) shares worth $199.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by McFarlane Neil F. on October 12, 2026 of 20,000 shares at $11.25 per share.
  • In the last 90 days, ZVRA insiders reported 0 open-market purchases ($0) and 1 open-market sale ($225K) on Form 4, a net sale of $225K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$106.5M
+350.9% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$225K
13F holders
26 funds
$199.9M · +0 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors since the March 31, 2026 Form 10-Q
  • Carried-forward risks remain those disclosed in the December 31, 2025 Form 10-K
  • Latest risk-factor update filed May 6, 2026 with the SEC

Management Discussion & Analysis

  • Revenue $37.8M, up $11.7M YoY, driven by MIPLYFFA product sales increasing $11.6M
  • Net income $19.2M vs $0.5M loss YoY, operating income $11.6M vs $4.1M
  • MIPLYFFA strongest product, $11.6M YoY sales increase; OLPRUVA revenue $0.2M and sales efforts scaled back
  • Cash, cash equivalents and investments $270.9M; nine-month operating cash flow $33.2M vs $(7.1)M
  • EMA CHMP negative opinion on arimoclomol, re-examination requested; continued celiprolol Phase 3 development and commercial spending

AI summary of the ZVRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and corporate updates announced for quarter ended September 30, 2026
  • Investor conference call and audio webcast scheduled for November 3, 2026, at 4:30 p.m. ET

Item EX-99.1: Item EX-99.1

  • Q3 revenue $37.8M, up $11.7M from Q3 2025, with MIPLYFFA contributing $34.0M
  • Net income $19.2M, or $0.26 diluted EPS, versus a $0.5M loss, aided by $5.1M warrant and CVR liability gains
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results and corporate updates announced for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive financial and operating details

Item EX-99.1: Item EX-99.1

  • Q2 net revenue $39.7M, up 53% YoY, with MIPLYFFA contributing $30.2M and global EAP reimbursements $9.0M
  • Net income $8.8M, or $0.14 diluted EPS, versus $74.7M in Q2 2025 distorted by a $148.3M priority-review-voucher gain
Filed Jun 5, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 78.37% of outstanding shares voted at the June 4, 2026 annual meeting
  • Douglas W. Calder and Corey Watton elected as Class II directors through 2029

AI summaries of ZVRA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ZVRA

Don't miss the next ZVRA filing

  • Alerts as it files. A push when ZVRA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ZVRA, by share count.
  • Ask anything. An AI agent that reads every ZVRA filing and answers with sources.

ZVRA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
McFarlane Neil F.SellOct 12, 2026$11.25
McFarlane Neil F.MOct 10, 2026-
McFarlane Neil F.MOct 10, 2026-
Thompson RahsaanSellAug 14, 2026$11.13
Watton Corey MichaelMAug 10, 2026-
Watton Corey MichaelMAug 10, 2026$4.97
Watton Corey MichaelSellAug 10, 2026$11.25
Thompson RahsaanSellJun 22, 2026$12.68

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$23.6M$106.5M
Operating Income--$87.0M-$62.9M
Net Income-$46.0M-$105.5M$83.2M
Op. Margin--368.5%-59.1%
Net Margin--446.9%78.2%
Balance Sheet
Total Assets$172.3M$178.1M$284.7M
Equity-$39.7M$154.7M
ROE--266.0%53.8%
Per Share
EPS$-1.30$-2.28$1.35
Cash Flow
Operating CF--$69.7M-$1.6M
CapEx$296K$0$835K

Source: XBRL data in ZEVRA THERAPEUTICS, INC. (ZVRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ZVRA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ZVRA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$199.9M
Q2 202626$299.3M
Q1 202625$168.4M
Q4 202523$164.3M
Q3 202522$149.6M
Q2 202520$115.6M
Q1 202518$59.7M
Q4 202414$61.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ZVRA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 3, 2026Analysis
8-KNov 3, 2026Analysis-
4Oct 13, 2026--
4Aug 17, 2026--
4Aug 12, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
SC 13GJul 31, 2026-
4Jun 23, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
8-KJun 5, 2026Analysis
4May 29, 2026-
4May 13, 2026-
SC 13GMay 6, 2026-
8-KMay 6, 2026Analysis
10-QMay 6, 2026Analysis
4Mar 26, 2026--
4Mar 19, 2026--
8-KMar 16, 2026Analysis-
10-KMar 9, 2026-

Related Health Care companies

All Health Care →

ZVRA SEC filings: frequently asked questions

Are ZVRA insiders buying or selling?

In the last 90 days, ZEVRA THERAPEUTICS, INC. (ZVRA) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $224,948 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ZVRA stock?

As of September 30, 2026, the largest ZEVRA THERAPEUTICS, INC. (ZVRA) holders among the 13F filers tracked by SignalX were BlackRock ($56.3 million), Vanguard Capital Management LLC ($28.8 million), State Street Corp ($22.5 million), Morgan Stanley ($16.7 million), D.E. Shaw & Co ($13.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ZVRA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.5 million (up 350.9% from FY2024) and net income of $83.2 million. Diluted EPS was $1.35. The figures come from the XBRL data in the 10-K.

What did ZVRA report in its latest 8-K?

ZEVRA THERAPEUTICS, INC. (ZVRA) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and corporate updates announced for quarter ended September 30, 2026.

What are the latest ZVRA SEC filings?

ZEVRA THERAPEUTICS, INC. (ZVRA) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 13, 2026.

What is ZVRA's SEC CIK number?

ZEVRA THERAPEUTICS, INC. (ZVRA)'s SEC Central Index Key (CIK) is 1434647. EDGAR lists every ZVRA filing under that number.

Ask anything about ZVRA

The research agent reads ZVRA's filings, financials, insider trades and 13F holders, then answers with sources.